Department of Medical Oncology, University General Hospital of Heraklion, Greece.
Crit Rev Oncol Hematol. 2010 Mar;73(3):220-7. doi: 10.1016/j.critrevonc.2009.03.006. Epub 2009 Apr 14.
To compare efficacy and tolerability of fulvestrant with aromatase inhibitors and tamoxifen that actually represent the standard of care in hormone-sensitive breast cancer.
Systematic review and meta-analysis of available trials. Primary outcomes were overall survival, time to progression, clinical outcome and objective response. Secondary outcome was the tolerability profile of the drugs.
Four trials were identified with 2125 eligible patients. There was no statistically significant difference between fulvestrant and other hormonal agents in terms of overall survival (pooled HR: 1.047, 95% CI: 0.688-1.592), time to progression (pooled HR: 0.994, 95% CI: 0.691-1.431), clinical benefit (pooled OR: 1.044, 95% CI: 0.828-1.315) or objective response rate (pooled OR: 0.949, 95% CI: 0.736-1.224). A higher incidence of joint disorders (pooled OR: 0.621, 95% CI: 0.424-0.909; P=0.014) was noted in patients receiving hormonal agents other than fulvestrant.
Fulvestrant was similar to other hormonal agents with respect to efficacy measures, with good tolerability profile.
比较氟维司群与芳香化酶抑制剂和他莫昔芬的疗效和耐受性，这两种药物实际上代表了激素敏感型乳腺癌的标准治疗方法。
对现有试验进行系统评价和荟萃分析。主要结局是总生存期、无进展生存期、临床结局和客观缓解率。次要结局是药物的耐受性特征。
确定了四项试验，共纳入 2125 名合格患者。氟维司群与其他激素药物在总生存期（合并 HR：1.047，95%CI：0.688-1.592）、无进展生存期（合并 HR：0.994，95%CI：0.691-1.431）、临床获益（合并 OR：1.044，95%CI：0.828-1.315）或客观缓解率（合并 OR：0.949，95%CI：0.736-1.224）方面无统计学差异。接受除氟维司群以外的激素药物治疗的患者发生关节疾病的发生率更高（合并 OR：0.621，95%CI：0.424-0.909；P=0.014）。
氟维司群在疗效方面与其他激素药物相似，具有良好的耐受性特征。
